-
Mashup Score: 18Part II: The treatment of primary and secondary Raynaud's phenomenon - 2 month(s) ago
Raynaud phenomenon (RP) presents with either primary or secondary disease, and both have the potential to negatively impact patient quality of life. First-line management of RP should include lifestyle modifications in all patients. Some patients with primary RP and most with secondary RP require pharmacologic therapies, which may include calcium channel blockers, topical nitrates, phosphodiesterase 5 inhibitors, or endothelin antagonists. Additional approaches to treatment for those with signs of critical ischemia or those who fail pharmacologic therapy include botulinum toxin injection and digital sympathectomy.
Source: www.jaad.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon - 3 month(s) ago
Raynaud’s phenomenon (RP) is a relatively common disease with both primary and secondary forms. It is well understood as a vasospastic condition affecting the acral and digital arteries, resulting in characteristic, well-demarcated color changes typically in the hands and feet in response to cold or stress. Secondary RP (SRP) has been described in association with a variety of rheumatologic and nonrheumatologic diseases, environmental exposures, and/or medications. While both primary RP and SRP may impact the quality of life, SRP may lead to permanent and potentially devastating tissue destruction when undiagnosed and untreated.
Source: www.jaad.orgCategories: General Medicine News, Partners & KOLsTweet-
#Raynaud's phenomenon (RP) is a common disease in which extremities experience changes in response to cold or stress. The skin plays a critical role in thermoregulation, making it vital for dermatologists to distinguish between primary RP and SRP early. https://t.co/kvtaUmp4C3 https://t.co/5l8igZqFK4
-
-
Mashup Score: 10Researchers Link Two Genes to Raynaud Disease - 6 month(s) ago
The discovery will hopefully lead to new therapeutic avenues for the condition, experts say.
Source: www.medscape.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1ADRA2A and IRX1 are putative risk genes for Raynaud’s phenomenon - 6 month(s) ago
Nature Communications – Raynaud’s phenomenon is a common vasospastic disorder, but the genetic origins of the condition are not well understood. Here, the authors find common genetic variants…
Source: www.nature.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 5Connective tissue disorders: practical assessment and management | British Society for Rheumatology - 12 month(s) ago
This is a one-day course aimed at the entire multidisciplinary team, providing a practical and comprehensive overview of how to assess, manage and monitor three key connective tissue disorders
Source: rheumatology.org.ukCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
We spoke with Dr. Kate Bedrin, one of the authors of “Raynaud’s phenomenon associated with calcitonin gene-related peptide receptor antagonists case report” …
Source: YouTubeCategories: Latest Headlines, NeurologyTweet-
🗣️ New @ahsheadache @HeadacheJournal interview! We spoke with Dr. Kate Bedrin, one of the authors of: #Raynaud's phenomenon associated with #CGRP receptor antagonists case report 🎙️Interview link: https://t.co/8qCnTEfIWZ Manuscript can be accessed with the link below! ⬇️ https://t.co/XIi8CIg23W https://t.co/uxLPVca8io
-
-
Mashup Score: 572-Year-Old Man With Puffy Fingers and Raynaud Phenomenon - 2 year(s) ago
A 72-year-old man, recently diagnosed with squamous cell carcinoma of the skin with left parotid gland metastasis (status postparotidectomy and radiation), hypothyroidism, hypertension, and allergic rhinitis presented with puffy fingers and Raynaud phenomenon (RP). Medications included acetaminophen, oxycodone, lisinopril, loratadine, senna, and multivitamins.
Source: Mayo Clinic ProceedingsCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Risk stratification using VEDOSS criteria can help identify individuals with Raynaud’s phenomenon who are most likely to progress to definite systemic sclerosis, study findings indicate.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
OnabotulinumtoxinA has been implemented as a treatment of intractable Raynaud phenomenon after failure with traditional treatments, such as calcium channel blockers, angiotensin receptor blockers, prostaglandins, endothelin receptor blockers, and phosphodiesterase 5 inhibitors.
Source: www.mdedge.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 2
OnabotulinumtoxinA has been implemented as a treatment of intractable Raynaud phenomenon after failure with traditional treatments, such as calcium channel blockers, angiotensin receptor blockers, prostaglandins, endothelin receptor blockers, and phosphodiesterase 5 inhibitors.
Source: www.mdedge.comCategories: Dermatology, Latest HeadlinesTweet
In Part II of the February CME, the authors describe in detail the treatment options for patients with #Raynaud phenomenon (RP), as well as provide treatment algorithms for each RP subtype. https://t.co/DHSQZBPKQh https://t.co/Yf0vyC92zG